Sildenafil Impact on Ventricular Function in Patients With Heart Failure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01936350|
Recruitment Status : Completed
First Posted : September 6, 2013
Last Update Posted : November 7, 2013
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure||Drug: Sildenafil Drug: Placebo||Phase 2 Phase 3|
Twenty-four patients with known heart failure will be recruited. They will undergo a cardiac magnetic resonance for ventricular analyses and after this first exam they will be randomized to placebo or sildenafil. After one hour drug intake they will undergo another cardiac magnetic resonance to evaluate the drug impact on right and left ventricular function.
The first and second exams will be performed by the same staff. All patients will be evaluated by two, three and four chambers view. Left and right ventricle quantification analyses will be performed by Argus software.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Sildenafil Impact on Ventricular Function in Patients With Heart Failure: Randomized Clinical Trial|
|Study Start Date :||September 2013|
|Actual Primary Completion Date :||November 2013|
|Actual Study Completion Date :||November 2013|
12 patients will be in this group. They will take a sildenafil 50mg.
The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.
Placebo Comparator: Placebo
12 patients will be in this group, they will take placebo
This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
Other Name: Placebo group
- Improvement on ventricular function [ Time Frame: one hour ]Patients will undergo a cardiac magnetic resonance to evaluate ventricular function after one hour of sildenafil or placebo use
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01936350
|Hospital Ana Neri - MRI unit|
|Salvador, Bahia, Brazil, 40000|
|Study Director:||Andre M Fernandes, Master||Hospital Ana Nery - Federal University of Bahia|